跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Glucagon analogue
首页
药物
Glucagon analogue
Glucagon analogue
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
ACYLATED GLUCAGON ANALOGUES
EP 3057984 B1
申请人: ZEALAND PHARMA AS
优先权: 2013
CN
EP
US
WO
13 件公开
CN 104961822 A
申请人: ZEALAND PHARMA AS
优先权: 2010
CN
US
3 件公开
Methods and compositions for treating hypoglycemic disorders
US 9821031 B2
申请人: STOFFERS DORIS
优先权: 2007
US
WO
10 件公开
FORMULATIONS OF GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES
US 2022265551 A1
申请人: ZEALAND PHARMA AS
优先权: 2018
CN
EP
US
WO
8 件公开
GLUCAGON-LIKE PEPTIDE-1 ANALOGUE AND USE THEREOF
EP 2565205 B1
申请人: BETTA PHARMACEUTICALS CO LTD
优先权: 2010
CN
EP
US
WO
4 件公开
LONG-ACTING GLP-1 AND GLUCAGON RECEPTOR DUAL AGONIST
US 2023220035 A1
申请人: DONG A ST CO LTD
优先权: 2020
CN
EP
US
WO
4 件公开
PROCESS FOR FORMULATING COMPOSITIONS COMPRISING GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES
EP 4398872 B1
申请人: ZEALAND PHARMA AS
优先权: 2021
CN
EP
US
WO
4 件公开
OIL BASED FORMULATIONS FOR SUBLINGUAL AND BUCCAL DELIVERY
EP 3589271 A4
申请人: BIOLINGUS IP LLC
优先权: 2017
CN
EP
US
3 件公开
COMBINATION THERAPY
EP 4735021 A1
申请人: ZEALAND PHARMA AS
优先权: 2023
CN
EP
WO
3 件公开
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OBESITY COMPRISING GLP ANALOGUE AS ACTIVE INGREDIENT
EP 4741420 A1
申请人: HUONSLAB CO LTD
优先权: 2023
CN
EP
WO
3 件公开
Glucagon analogues
US 9169310 B2
申请人: RIBER DITTE
优先权: 2011
CN
US
3 件公开
US 2015111817 A1
申请人: ZEALAND PHARMA AS
优先权: 2013
CN
US
3 件公开
US 8685919 B2
申请人: MEIER EDDI
优先权: 2008
US
3 件公开
US 8642540 B2
申请人: MEIER EDDI
优先权: 2008
US
3 件公开
US 8642541 B2
申请人: MEIER EDDI
优先权: 2008
US
3 件公开
US 2013157935 A1
申请人: MEIER EDDI
优先权: 2011
CN
US
2 件公开
US 2013316941 A1
申请人: BOEHRINGER INGELHEIM INT
优先权: 2012
CN
US
2 件公开
US 7994122 B2
申请人: ZEALAND PHARMA AS
优先权: 2008
US
2 件公开
US 8680049 B2
申请人: MEIER EDDI
优先权: 2008
US
2 件公开
EP 2025684 A1
申请人: ZEALAND PHARMA AS
优先权: 2007
EP
US 2014080757 A1
申请人: BOEHRINGER INGELHEIM INT
优先权: 2013
US
第 1 / 9 页
上一页
下一页
药物
反馈